We’re pleased to announce that in January 2019 a regular inspection of Good Manufacturing Practice was conducted by the State Institute for Drug Control in Prague. On the basis of their findings a GMP Certificate will be issued to the full extent of our authorization to manufacture medicinal products. The inspection report will also be provided to the US FDA under the MRA agreement (mutual recognition of GMP inspection results) between the US and EU. Quinta-Analytica is one of the first companies whose inspection report has been requested by the US FDA from the State Institute for Drug Control, and we’re honored to receive this recognition.”

Additional News

  • 16 December 2024

    Welcome, 2025!

    Reflecting on 2024 with gratitude and looking ahead with optimism.

  • 2 December 2024

    A Decade of Partnership with Adamed Pharma

    Adamed Pharma and Quinta-Analytica’s 10 – Year Journey in Pharma Innovation

  • 25 November 2024

    Expediting Biosimilar development: Streamlining the path from research to market

    On behalf of the Conscio Group, we would like to invite you to a free webinar on the future of the biosimilar pathway to approval, which is now open for registration.